Join to view full profile
201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194
Dr. Denmeade is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Director of the Genitourinary Oncology Program at Johns Hopkins in Baltimore, MD. He is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 28 years. He is experienced in treatment of advanced prostate cancer. He has more than 200 publications and developed the concept of Bipolar Androgen Therapy for metastatic prostate cancer
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
University of ChicagoResidency, Internal Medicine, 1989 - 1992
Columbia University Vagelos College of Physicians and SurgeonsClass of 1989
Certifications & Licensure
MD State Medical License 1993 - 2028
PA State Medical License 1992 - 2026
VA State Medical License 2024 - 2026
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Castration Resistance Accelerates Prostate Cancer Kinetics.Sheila Jonnatan, Luka Cavka, Angelo M De Marzo, Samuel R Denmeade, Mark C Markowski
The Prostate. 2026-06-01 - WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific...Barak Talmor, Carole A Harris, Christopher Gianacas, David Pook, Thean Hsiang Tan
European Urology Oncology. 2026-04-01 - 4 citationsAndrogen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer.Rajendra Kumar, Sheila Jonnatan, David E Sanin, Varsha Vakkala, Anoushka Kadam
Cancer Research. 2026-03-02
Journal Articles
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerEmmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
Press Mentions
Prostate Cancer Drug Is Found to Be an Effective Antiviral Against Coronavirus and the Common ColdFebruary 3rd, 2021
Health Tips: This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 29th, 2017
Health Tips This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 28th, 2017
Grant Support
- SPORE in Prostate CancerJOHNS HOPKINS UNIVERSITY2024–2029
- Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune ResponseJOHNS HOPKINS UNIVERSITY2021–2027
- The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate CancerJOHNS HOPKINS UNIVERSITY2023–2025
Other Languages
- Spanish
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/samuel-denmeade
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
